Takeda Chemical Industries, Inc.

Shimadzu Corporation

Tokyo Metropolitan Institute of Medical Science

Susumu Iwasa

Masafumi Misaki

Yutaka Yamagata

Tomofumi Kurokawa

Shigeyuki Takada

Yukio Toyoda

Isamu Yoshida

Naoki Nagahara

Yohko Akiyama

Koichi Kondo

Tetsuo Hoshino

Masafumi Nakao

Kaori Harada

Hiroko Tada

Osamu Nishimura

Mitsuhiro Wakimasu

Shigehisa Taketomi

Koichi Igarashi

Kazuhiro Saito

Ryuji M Marumoto

Shigezo Udaka

Jun Sato

Hideo Yamagata

Makoto Watanabe

Toshiya Matsubara

Yasushi Nakagawa

Hayao Ueno

Tomoko Fujii

Kenjiro Tanoue

Hiroh Yamazaki

Yasushi Inoue

Akiko Watanabe

Hiroya Muranishi

An insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance are provided. The insulin resistance marker includes a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence of SEQ ID NO: 1 (sequence of a proepithelin protein). The insulin resistance marker includes a polynucleotide selected from the group consisting of (1) a polynucleotide comprising at least any 45 continuous bases in the base sequence of SEQ ID NO:2 encoding the above specific amino acid sequence, and (2) a polynucleotide that is complementary to the polynucleotide of (1).

Method of screening a substance for improving insulin resistance

A method for producing a sustained-release preparation, which comprises dispersing a physiologically active polypeptide into an organic solvent solution of a biodegradable polymer and removing the organic solvent, wherein the polypeptide is a powder obtained by lyophilizing an aqueous solution of the polypeptide which solution has a water-miscible organic solvent and/or a volatile salt; which improves the ease of handling of the physiologically active polypeptide powder in the process for producing the preparation; which makes it possible to industrially produce the sustained-release preparation in large scale; which provides a sustained-release preparation showing high and stable concentration of the active component in blood in long term, low initial release ratio of the physiologically active polypeptide, and high entrapment ratio of the polypeptide into the sustained-release preparation.

Sustained-release preparation of physiologically active polypeptide and production thereof

The present invention provides a complex of human growth hormone and zinc containing human growth hormone and zinc at a molar ratio of about 1:1.6 to about 1:2.4, and a sustained-release preparation which comprises the complex of human growth hormone and zinc and a biodegradable polymer and which has a high entrapment ratio of human growth hormone and exhibits a stable sustained-release suppressing the initial burst.

Complex of human growth hormone and zinc and use

A method of producing sustained-release microcapsules which comprises dispersing a physiologically active polypeptide into a solution of a biodegradable polymer and zinc oxide in an organic solvent, followed by removing the organic solvent; which provides a sustained-release preparation showing a high entrapment ratio of the physiologically active polypeptide and its constant high blood concentration levels over a long period of time.

Method of producing a sustained-release preparation

The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against,(HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.

Formulation comprising antibacterial substance and antiulcer substance

Complex of human growth hormone and zinc

This invention provides a pharmaceutical composition comprising a non-peptide osteogenesis-promoting substance and a polyethylene glycol or a derivative thereof, which can be advantageously used as a agent for preventing or treating various bone diseases (e.g., osteoporosis) in view of the high oral absorbability and stability of the active ingredient.

Pharmaceutical composition containing osteogenesis-promoting substance

A sustained-release preparation containing a bioactive polypeptide is prepared using a starting material containing a lyophilized product of an aqueous solution or suspension of the bioactive polypeptide in a non-ionic surfactant. The lyophilized product is dispersed in an oil phase, which further contains a biocompatible, biodegradable polymer.

Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase

A sustained-release microcapsule contains an amorphous water-soluble pharmaceutical agent having a particle size of from 1 nm-10 .mu.m and a polymer. The microcapsule is produced by dispersing, in an aqueous phase, a dispersion of from 0.001-90% (w/w) of an amorphous water-soluble pharmaceutical agent in a solution of a polymer having a wt. avg. molecular weight of 2,000-800,000 in an organic solvent to prepare an s/o/w emulsion and subjecting the emulsion to in-water drying.

Sustained-release microcapsule of amorphous water-soluble pharmaceutical

Substained release microcapsule of physiologically active compound which

The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an anti ulcer agent, showing potent anti-HP activity.

This invention provides a pharmaceutical composition comprising a non-peptide osteogenic promoting substance and a biodegradable polymer, which can be safely used as a prophylactic/therapeutic agent for various bone diseases (e.g., bone fractures).

Osteogenic promoting pharmaceutical composition

A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous phase a dispersion of the amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof in a solution of a polymer in an organic solvent to give an s/o/w type emulsion and subjecting the emulsion to in-water drying. The sustained-release microcapsule entraps 2-piperazinone-1-acetic acid compound or the salt thereof, as a drug, in high concentration, and in reducing the initial release of the drug, thereby reducing undesirable side effects of the drug.

Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic

Injectable composition and a method of producing the same

Growing community of inventors

Kyotanabe, Japan

Susumu Iwasa